Department of Cardiology, Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA.
Division of Cardiology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Can J Cardiol. 2024 May;40(5):907-920. doi: 10.1016/j.cjca.2024.01.013. Epub 2024 Jan 18.
Hypertrophic cardiomyopathy (HCM) is a primary heart muscle disease characterized by left ventricular hypertrophy that can be asymptomatic or with presentations that vary from left ventricular outflow tract obstruction, heart failure from diastolic dysfunction, arrhythmias, and/or sudden cardiac death. Children younger than 1 year of age tend to have worse outcomes and often have HCM secondary to inborn errors of metabolism or syndromes such as RASopathies. For children who survive or are diagnosed after 1 year of age, HCM outcomes are often favourable and similar to those seen in adults. This is because of sudden cardiac death risk stratification and medical and surgical innovations. Genetic testing and timely cardiac screening are paving the way for disease-modifying treatment as gene-specific therapies are being developed.
肥厚型心肌病(HCM)是一种原发性心肌疾病,其特征为左心室肥厚,可无症状,也可表现为左心室流出道梗阻、舒张功能障碍性心力衰竭、心律失常和/或心源性猝死。1 岁以下的儿童往往预后较差,常因先天性代谢异常或 RAS 病等综合征继发 HCM。对于 1 岁以后存活或诊断的儿童,HCM 的结局通常较好,与成人相似。这是因为对心脏性猝死风险进行了分层,以及医疗和外科创新。基因检测和及时的心脏筛查为疾病修饰治疗铺平了道路,因为正在开发针对特定基因的治疗方法。